What Medications Are Used in Detox? Alcohol, Opioid, Benzo and Stimulant Care

Detox medications are not one category of drugs doing the same job. Some prevent dangerous withdrawal complications, some reduce symptoms, and some treat the underlying substance use disorder itself. The most important distinction is whether a medication is being used only for short-term withdrawal management or should continue after detox as ongoing addiction treatment.

Alcohol, opioids and benzodiazepines require very different medication strategies. Stimulant withdrawal is different again because there is no approved replacement medication comparable with methadone or buprenorphine for opioid use disorder.

Detox Medications at a Glance

How to Read a Detox Medication Plan

A useful medication list should tell you more than drug names. It should show which medication is preventing dangerous withdrawal, which is only reducing symptoms, which treats the substance use disorder itself, and which should continue after the withdrawal episode ends. Those roles are often different.

This distinction affects discharge planning. A short course of medication for alcohol withdrawal may appropriately stop when acute risk resolves, while buprenorphine or methadone may need to continue because they are ongoing OUD treatment. Comfort medication for nausea or diarrhea may end quickly, while a benzodiazepine taper may continue for much longer.

It also changes how “success” is interpreted. A patient whose symptoms improve on lofexidine has completed symptom treatment, not OUD treatment. A patient stabilized on buprenorphine has not failed detox because an opioid medication remains on the medication list. The medication is serving a different clinical purpose.

A medication can make withdrawal more comfortable without treating the addiction. Another medication can do both. Confusing those roles can create poor discharge planning.

For example, lofexidine can reduce opioid-withdrawal symptoms, but buprenorphine or methadone treat OUD itself. A patient who finishes a lofexidine-assisted withdrawal still needs an evidence-based OUD plan.

Medications Used for Alcohol Withdrawal and AUD

Benzodiazepines and complication prevention

Benzodiazepines are a central medication class for clinically significant alcohol withdrawal because they reduce withdrawal severity and help prevent seizures and delirium. The exact regimen depends on severity, medical status, setting and the clinician’s protocol.

They are short-term withdrawal medications in this context. They are not long-term treatment for alcohol use disorder.

Why thiamine matters

Long-term heavy alcohol use can be associated with thiamine deficiency. Severe deficiency can contribute to Wernicke encephalopathy, a neurologic emergency involving confusion, coordination problems and abnormal eye movements.

Thiamine given during alcohol withdrawal is therefore nutritional and neurologic treatment. It should not be confused with commercial vitamin infusions marketed as general detoxification.

Phenobarbital in selected protocols

Some experienced medical settings use phenobarbital in selected alcohol-withdrawal protocols. It can be effective, but it has important sedative and respiratory risks and belongs in clinician-directed treatment with appropriate monitoring.

Its presence in medical protocols does not make it an at-home detox medication.

Medications that treat AUD after withdrawal

SAMHSA identifies naltrexone, acamprosate and disulfiram as common FDA-approved medications used in AUD treatment. They have different roles.

Naltrexone

Naltrexone can reduce alcohol’s reinforcing effects and help reduce heavy drinking or support abstinence. It is not a treatment for acute alcohol withdrawal.

Acamprosate

Acamprosate is used after alcohol cessation to support abstinence and reduce craving. SAMHSA notes that it is usually started after withdrawal symptoms have largely resolved. It does not treat acute withdrawal.

Disulfiram

Disulfiram creates an unpleasant reaction if alcohol is consumed. It does not reduce craving and does not treat alcohol withdrawal. It is most useful when adherence and the patient’s treatment goals fit its deterrent mechanism.

Medications Used for Opioid Withdrawal and OUD

Buprenorphine and methadone treat more than withdrawal

Buprenorphine and methadone suppress opioid withdrawal and craving while treating opioid use disorder. SAMHSA states that these medications can be used for months, years or even a lifetime when clinically appropriate.

This is the clearest example of why “detox medication” can be a misleading label. Stopping buprenorphine or methadone automatically when the withdrawal stay ends can remove the very treatment reducing relapse and overdose risk.

Buprenorphine and initiation timing

Buprenorphine has high affinity for opioid receptors. Traditional initiation generally occurs when sufficient opioid withdrawal is present so the medication does not abruptly displace a full agonist and worsen symptoms.

The exact induction strategy depends on the opioids involved and the clinical setting. Fentanyl exposure has made rigid hour-count rules less reliable, which is why the plan should be clinician guided rather than copied from a generic online schedule.

Methadone and ongoing OUD treatment

Methadone is a full opioid agonist used to treat OUD. It reduces withdrawal and craving and can continue long term. In the United States, methadone for OUD is generally provided through federally certified opioid treatment programs.

Its long duration and respiratory-depressant potential mean dosing and interactions require careful clinical management.

Lofexidine treats symptoms, not the underlying OUD

Lofexidine is FDA approved to mitigate opioid-withdrawal symptoms to facilitate opioid discontinuation in adults. It reduces noradrenergic withdrawal symptoms but does not block opioid effects, reduce overdose risk in the way sustained MOUD does, or treat the behavioral disorder by itself.

This distinction should be explicit at discharge: feeling better after lofexidine-assisted withdrawal does not mean OUD treatment is complete.

Naltrexone and the opioid-free interval

Naltrexone blocks opioid receptors rather than activating them. If given while physiologic opioid dependence is still present, it can precipitate severe withdrawal. The patient therefore needs an adequate opioid-free interval before initiation.

This makes naltrexone fundamentally different from buprenorphine and methadone, which can be started as part of withdrawal treatment.

Benzodiazepine and Stimulant Withdrawal Require Different Medication Logic

Benzodiazepine dependence is usually managed with a taper

The 2025 ASAM-led joint guideline advises against abrupt discontinuation in physically dependent patients and supports gradual, individualized tapering. Some clinicians may transition a patient to a longer-acting benzodiazepine in selected cases, but this is not appropriate for every patient.

The taper rate can be slowed or paused when symptoms become clinically significant. A longer taper is not treatment failure. It is often a safer response to physiologic dependence.

Why OUD treatment should not automatically be withheld because of benzodiazepines

Patients with OUD may also use benzodiazepines. The combination increases overdose risk and requires careful management, but effective OUD treatment should not automatically be denied solely because benzodiazepines are present.

The treatment plan should reduce sedative risk while preserving evidence-based OUD care.

Stimulant withdrawal has no standard replacement medication

Cocaine and methamphetamine withdrawal usually centers on sleep, nutrition, mood, craving and psychiatric safety. There is no FDA-approved medication that directly replaces the stimulant during withdrawal in the way methadone can stabilize opioid use disorder.

Medication may still be used for specific psychiatric symptoms or co-occurring disorders, but that is symptom-directed care rather than a universal stimulant-detox protocol.

Medication Safety, Patient Factors and Discharge Continuity

Comfort medications are helpful but easy to overstate

Anti-nausea medication, antidiarrheals, non-opioid pain relievers, sleep medication and blood-pressure agents can improve tolerability. They should be selected with awareness of sedation, blood pressure, liver or kidney disease and the rest of the medication list.

Comfort treatment is valuable, but it should not distract from the medication that treats the underlying disorder when such treatment exists.

Medication reconciliation at discharge

Before leaving detox, the patient should know which medications stop, which continue, who will prescribe the next supply and when follow-up occurs. This is particularly important for buprenorphine, methadone, psychiatric medication and ongoing benzodiazepine tapers.

A medication gap created by discharge logistics can undo otherwise excellent withdrawal management.

Why liver, kidney, pregnancy and sedation risk change medication choice

Detox medication is not selected from the substance name alone. Liver disease can change how some sedatives are handled. Kidney function matters for medications cleared primarily through the kidneys. Pregnancy changes the risk-benefit analysis for both withdrawal and addiction medication. Concurrent opioids, alcohol or benzodiazepines can amplify sedation and respiratory risk.

This is why two patients with the same stated drug of dependence may receive different plans. Medication choice, monitoring intensity and the setting are linked decisions. A medication that is reasonable with frequent observation may be inappropriate in an unsupervised environment.

When the withdrawal medication and addiction medication are different

Alcohol is a good example. Benzodiazepines may be used for acute withdrawal, while naltrexone, acamprosate or disulfiram address alcohol use disorder after the withdrawal phase. The medication that prevents a withdrawal seizure is not necessarily the medication that reduces future drinking.

Opioid treatment can be different because buprenorphine and methadone can bridge both phases. They relieve withdrawal and continue as treatment for OUD. Understanding this distinction prevents a common discharge error in which every medication given during detox is assumed to be temporary.

Questions to ask about detox medications

• Is this medication treating withdrawal, addiction, or both?
• Does it stop when detox ends?
• What side effects should be watched for?
• Can it interact with alcohol, benzodiazepines or opioids?
• Who prescribes it after discharge?
• What happens if the pharmacy or receiving program cannot provide it?

Frequently Asked Questions About Detox Medications

What medication is used for alcohol detox?

Benzodiazepines are a central evidence-based treatment for clinically significant alcohol withdrawal, with other supportive treatments used according to risk.

What medication is used for opioid detox?

Buprenorphine and methadone can treat withdrawal while also treating OUD. Lofexidine can reduce withdrawal symptoms but does not itself treat OUD.

Is Suboxone only a detox medication?

No. Buprenorphine-containing medication can continue as long-term treatment for opioid use disorder.

Is there a medication for stimulant withdrawal?

There is no FDA-approved stimulant-withdrawal replacement medication comparable with MOUD.

Should benzodiazepines be stopped abruptly in detox?

Physically dependent patients generally should not stop abruptly and should use an individualized supervised taper.

Sources

• The ASAM Criteria, Fourth Edition: current continuum of care, level-of-care assessment, reassessment and integration of withdrawal management into the broader addiction-treatment continuum.
• ASAM Criteria FAQ: current Fourth Edition withdrawal-management mapping, inpatient vs residential distinctions and least-intensive-safe-level principles.
• SAMHSA Evidence-Based Practices Resource Center: TIP 45: evaluation, stabilization and transition into continuing substance-use treatment.
• SAMHSA Treatment Options for Substance Use Disorder: medications, behavioral treatment and individualized treatment-setting selection.

Medication Sources

• SAMHSA TIP 63: Medications for Opioid Use Disorder: buprenorphine, methadone and naltrexone treatment.
• SAMHSA: Medications, Counseling, and Related Conditions: current AUD and OUD medication overview.
• ASAM Alcohol Withdrawal Management Guideline: ambulatory and inpatient withdrawal treatment and transition into AUD care.
• Joint Clinical Practice Guideline on Benzodiazepine Tapering, 2025: individualized gradual tapering and avoidance of abrupt discontinuation in physically dependent patients.
• FDA: Lofexidine approval information: lofexidine is indicated to mitigate opioid-withdrawal symptoms to facilitate opioid discontinuation in adults.